
Riten Kumar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1439203/publications.pdf Version: 2024-02-01



RITEN KIIMAR

#	Article	IF	CITATIONS
1	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology,the, 2020, 7, e18-e27.	4.6	173
2	Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood, 2021, 138, 190-198.	1.4	154
3	Pediatric histiocytic sarcoma clonally related to precursor Bâ€cell acute lymphoblastic leukemia with homozygous deletion of <i>CDKN2A</i> encoding p16 ^{INK4A} . Pediatric Blood and Cancer, 2011, 56, 307-310.	1.5	56
4	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€Jr phase 3 doseâ€exposureâ€response evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 1672-1685.	3.8	52
5	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematology,the, 2019, 6, e500-e509.	4.6	51
6	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Advances, 2020, 4, 6250-6258.	5.2	49
7	Inherited Abnormalities of Coagulation. Pediatric Clinics of North America, 2013, 60, 1419-1441.	1.8	34
8	Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Advances, 2018, 2, 285-291.	5.2	32
9	Rare Presentations of Primary Melanoma and Special Populations. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 635-641.	1.3	30
10	Health-related quality of life in children and young adults with post-thrombotic syndrome: Results from a cross-sectional study. Pediatric Blood and Cancer, 2014, 61, 546-551.	1.5	29
11	Risk Factors for Neonatal Venous and Arterial Thromboembolism in the Neonatal Intensive Care Unit—A Case Control Study. Journal of Pediatrics, 2018, 195, 28-32.	1.8	29
12	Prevalence and risk factors for post thrombotic syndrome after deep vein thrombosis in children: A cohort study. Thrombosis Research, 2015, 135, 347-351.	1.7	25
13	Congenital Thrombocytopenia. Hematology/Oncology Clinics of North America, 2013, 27, 465-494.	2.2	21
14	A Short Course of Prednisone in the Management of Acute Chest Syndrome of Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2010, 32, e91-e94.	0.6	20
15	Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. Pediatric Blood and Cancer, 2011, 57, 317-320.	1.5	19
16	Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Seminars in Thrombosis and Hemostasis, 2016, 42, 018-029.	2.7	19
17	Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study. Journal of Pediatrics, 2018, 197, 186-190.e1.	1.8	19
18	Valproic Acid–Induced Coagulopathy. Pediatric Neurology, 2019, 98, 25-30.	2.1	17

Riten Kumar

#	Article	IF	CITATIONS
19	Pelvic pseudotumor and pseudoaneurysm in a pediatric patient with moderate hemophilia B: Successful management with arterial embolization and surgical excision. Pediatric Blood and Cancer, 2011, 56, 484-487.	1.5	16
20	Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. British Journal of Haematology, 2014, 166, 130-139.	2.5	16
21	Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children. Chest, 2022, 161, 791-802.	0.8	15
22	Thrombosis of the Abdominal Veins in Childhood. Frontiers in Pediatrics, 2017, 5, 188.	1.9	14
23	Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia. Thrombosis and Haemostasis, 2016, 115, 1120-1128.	3.4	13
24	Successful treatment of a child with T/myeloid acute bilineal leukemia associated with <i>TLX3/BCL11B</i> fusion and 9q deletion. Pediatric Blood and Cancer, 2011, 56, 467-469.	1.5	12
25	Treatment-Related Outcomes in Paget–Schroetter Syndrome—A Cross-Sectional Investigation. Journal of Pediatrics, 2019, 207, 226-232.e1.	1.8	12
26	Inferior vena cava atresia predisposing to acute lower extremity deep vein thrombosis in children: A descriptive dualâ€center study. Pediatric Blood and Cancer, 2018, 65, e26785.	1.5	11
27	Anti-Factor Xa–Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. Journal of Pediatrics, 2019, 209, 212-219.e1.	1.8	11
28	Development and initial validation of a questionnaire to diagnose the presence and severity of postâ€ŧhrombotic syndrome in childre. Pediatric Blood and Cancer, 2012, 58, 643-644.	1.5	9
29	Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biology of Blood and Marrow Transplantation, 2018, 24, 337-342.	2.0	8
30	A Review of Venous Thromboembolism Risk Assessment and Prophylaxis in Plastic Surgery. Plastic and Reconstructive Surgery, 2022, 149, 121e-129e.	1.4	8
31	Catheterâ€directed thrombolysis for submassive pulmonary embolism in children: A case series. Pediatric Blood and Cancer, 2020, 67, e28144.	1.5	7
32	A novel mutation in the <i>SerpinC1</i> gene presenting as unprovoked neonatal cerebral sinus venous thrombosis in a kindred. Pediatric Blood and Cancer, 2013, 60, 133-136.	1.5	6
33	Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience. Journal of Pediatric Hematology/Oncology, 2017, 39, 576-577.	0.6	4
34	Popliteal Artery Entrapment Syndrome Presenting with Critical Limb Ischemia in an Adolescent. Journal of Pediatrics, 2020, 217, 215-215.e1.	1.8	4
35	Pretransplant Conditioning With Campath-1H (Alemtuzumab) in Pediatric Matched Unrelated Hematopoietic Stem Cell Transplants. Journal of Pediatric Hematology/Oncology, 2012, 34, 96-100.	0.6	3
36	c.1058C>T variant in the <i>SERPINC1</i> gene is pathogenic for antithrombin deficiency. British Journal of Haematology, 2015, 170, 123-125.	2.5	3

RITEN KUMAR

#	Article	IF	CITATIONS
37	aPTT in children receiving UFH: time for a change?. Blood, 2015, 126, 2075-2076.	1.4	3
38	Thrombocytopenia Pitfalls: Misdiagnosing Type 2B von Willebrand Disease as Ethylenediaminetetraacetic Acidâ `Dependent Pseudothrombocytopenia. Journal of Pediatrics, 2016, 175, 238-238.e1.	1.8	3
39	Molecular structural analysis of a novel and deâ€novo mutation in the <i><scp>SERPINC</scp>1</i> gene associated with type 1 antithrombin deficiency. British Journal of Haematology, 2017, 177, 654-656.	2.5	3
40	Klinefelter syndrome as a risk factor for recurrent deep vein thrombosis in an adolescent male: Significance of a thorough physical examination. Pediatric Blood and Cancer, 2018, 65, e27080.	1.5	3
41	Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatric Blood and Cancer, 2018, 66, e27588.	1.5	3
42	Unfractionated heparin using actual body weight without dose capping in obese pediatric patients—Subgroup analysis from an observational cohort study. Pediatric Blood and Cancer, 2021, 68, e28872.	1.5	3
43	Venous thoracic outlet syndrome and Paget-Schroetter syndrome. Seminars in Pediatric Surgery, 2021, 30, 151125.	1.1	3
44	Postradiation Dermatofibrosarcoma Protuberans in a Patient With Wilms Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, 635-636.	0.6	2
45	Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatric Blood and Cancer, 2019, 66, e27832.	1.5	2
46	Bleeding Severity and Phenotype in 22q11.2 Deletion Syndrome—A Cross-Sectional Investigation. Journal of Pediatrics, 2021, 235, 220-225.	1.8	2
47	Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists. Thrombosis Research, 2022, 211, 133-139.	1.7	2
48	Mesoaortic compression of a leftâ€sided inferior venaâ€cava presenting as recurrent pulmonary embolism in a child—a novel anatomic thrombophilia?. Pediatric Blood and Cancer, 2018, 65, e26986.	1.5	1
49	Fibrinogen Columbus III: A novel c.963del frameshift mutation in the <i>FGG</i> gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatric Blood and Cancer, 2021, 68, e28713.	1.5	1
50	Venous thromboembolism in children with central nervous system tumors: Comparison of an institutional cohort to a national administrative database. Pediatric Blood and Cancer, 2021, 68, e28846.	1.5	1
51	A Short Course of Prednisone in the Management of Acute Chest Syndrome of Sickle Cell Disease Blood, 2008, 112, 1417-1417.	1.4	0
52	Pretransplant Conditioning with Campath-1H (Alemtuzumab) in Pediatric Matched Unrelated Bone Marrow Transplants - An Institutional Experience Blood, 2009, 114, 4651-4651.	1.4	0
53	Thrombocytopenia and Platelet Ultra-Structural Abnormalities Associated with RUNX1 Haploinsufficiency in Monosomy 21 Mosaicism Blood, 2012, 120, 2190-2190.	1.4	0
54	Impact of Exercise on Hemostasis in Boys with Hemophilia a (HA) and B (HB): Principal Findings of the Sickkids Hemophilia Exercise Study. Blood, 2014, 124, 1493-1493.	1.4	0

RITEN KUMAR

#	Article	IF	CITATIONS
55	Risk Factors for Neonatal Thrombosis in the Neonatal Intensive Care Unit -a Case Control Study. Blood, 2015, 126, 1109-1109.	1.4	Ο
56	Jacobsen/Paris-Trousseau Syndrome: Report of a Case with Emphasis on Platelet's Light Microscopic and Ultrastructure Findings. Open Journal of Pathology, 2016, 06, 8-13.	0.2	0
57	Approach to a Child with Epistaxis and Macrothrombocytopenia. , 2020, , 195-203.		Ο
58	Recognition and Management of Congenital Platelet Granule Disorders. , 2020, , 205-218.		0